Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. 1996

S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
Laboratoire de Pharmacologie, Faculté de Médecine, Créteil, France.

The binding of docetaxel to human plasma proteins was studied by ultrafiltration at 37 degrees C and pH 7.4. Docetaxel was extensively (> 98%) plasma protein bound. At clinically relevant concentrations (1-5 micrograms/ml), the plasma binding was concentration-independent. Lipoproteins, alpha1-acid glycoprotein and albumin were the main carriers of docetaxel in plasma, and owing to the high interindividual variability of alpha1-acid glycoprotein plasma concentration, particularly in cancer, it was concluded that alpha1-acid glycoprotein should be the main determinant of docetaxel plasma binding variability. Drugs potentially coadministered with docetaxel (cisplatin, dexamethasone, doxorubicin, etoposide, vinblastine) did not modify the plasma binding of docetaxel. In blood, docetaxel was found to be mainly located in the plasma compartment (less than 15% associated to erythrocytes).

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009961 Orosomucoid Acid Seromucoid,Seromucoid,Serum Sialomucin,alpha 1-Acid Glycoprotein,alpha 1-Acid Seromucoid,A(1)-Acid Seromucoid,Acid alpha 1-Glycoprotein,Alpha(1)-Acid Glycoprotein,alpha 1-Acid Glycoprotein (Acute Phase),alpha 1-Glycoprotein Acid,Acid alpha 1 Glycoprotein,Glycoprotein, alpha 1-Acid,Seromucoid, Acid,Seromucoid, alpha 1-Acid,Sialomucin, Serum,alpha 1 Acid Glycoprotein,alpha 1 Acid Seromucoid,alpha 1 Glycoprotein Acid
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris

Related Publications

S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
May 1997, Pharmacology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
May 1980, Pharmakopsychiatrie, Neuro-Psychopharmakologie,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
April 1983, Biochemical pharmacology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
January 1989, Progress in clinical and biological research,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
May 1985, Biochemical pharmacology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
March 1991, International journal of clinical pharmacology, therapy, and toxicology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
September 1984, Clinical pharmacology and therapeutics,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
October 1992, The Journal of pharmacy and pharmacology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
January 1992, European journal of clinical pharmacology,
S Urien, and J Barré, and C Morin, and A Paccaly, and G Montay, and J P Tillement
January 2022, Journal of biomolecular structure & dynamics,
Copied contents to your clipboard!